Release
📈 Stocks
Zealand Pharma's Survodutide Hits Primary Endpoint in Phase 3 CVOT Trial
(just now)
Survodutide met its primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial, showing significant cardiometabolic benefits including weight loss of up…